SCHEMBL1716895

SCHEMBL1716895

CCOC(=O)N1CCN(Cc2c(C(=O)NC(CC)c3ccccc3)c3ccccc3c(=O)n2-c2ccccc2)CC1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 6/20 0.45
TACR2 P21452 5/20 0.45
OPRM1 P35372 4/20 0.45
HIF1A Q16665 1/20 0.44
ALDH1A1 P00352 6/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 1/20 0.44
GAA P10253 2/20 0.44
KDM4E B2RXH2 4/20 0.43
MAPT P10636 3/20 0.43
TSHR P16473 2/20 0.42
MCL1 Q07820 1/20 0.42
ATM Q13315 1/20 0.42
ITGA4 P13612 1/20 0.42
ITGB7 P26010 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
P4HB P07237 1/20 0.41
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1723402 0.93 TACR3 (0.43) TACR3TACR2OPRM1HIF1AALDH1A1
SCHEMBL1717901 0.93 TACR3 (0.43) TACR3TACR2OPRM1HIF1AALDH1A1
SCHEMBL1717680 0.91 TACR3 (0.43) TACR3TACR2OPRM1
SCHEMBL1717435 0.90 TACR3 (0.47) TACR3TACR2OPRM1HIF1AALDH1A1
SCHEMBL1718231 0.89 TACR3 (0.49) TACR3TACR2OPRM1HIF1AALDH1A1
SCHEMBL1718098 0.89 TACR3 (0.43) TACR3TACR2OPRM1HIF1AALDH1A1
SCHEMBL1717085 0.89 TACR3 (0.49) TACR3TACR2OPRM1
SCHEMBL1717859 0.88 TACR3 (0.48) TACR3TACR2OPRM1HIF1AALDH1A1
SCHEMBL1717555 0.88 TACR3 (0.48) TACR3TACR2OPRM1HIF1AALDH1A1
SCHEMBL1717937 0.88 TACR3 (0.54) TACR3TACR2OPRM1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US claimed
EP-2150534-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-01-11 EP claimed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
EP-2150534-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-01-11 EP disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 TACR3 30/4885TACR2 31/4885OPRM1 892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.